MAPT and Alzheimer disease: A commonly used approach is the biomarker-based assessment of Aβ (A), pathological tau (T) and neurodegeneration (N) markers.14 This recognizes A(+)T(+)N(+/−) as predicting AD and A(−)T(+)N(+/−) as non-AD pathologic change.